Table 1.
Treatment regimens used for patients with stage I anaplastic histology Wilms tumor enrolled on NWTS 1–5
| Study | Regimen Name | Chemotherapy Regimen | XRT | # patients (FA/DA) |
|---|---|---|---|---|
| NWTS-1 | A | AMD × 15 mo | Yes | 0/2 |
| B | AMD × 15 mo | No | 0/2 | |
| NWTS-2 | C | AMD/VCR × 15 mo | Yes | 1/0 |
| D | VCR/AMD/DOX × 15 mo | Yes | 0/1 | |
| E | VCR/AMD × 6 mo | No | 1/1 | |
| F | VCR/AMD × 15 mo | No | 0/4 | |
| NWTS-3 | DD | VCR/AMD/DOX × 15 mo | No | 1/2 |
| DD-RT/DD2000 | VCR/AMD/DOX × 15 mo | Yes | 2/8 | |
| EE | VCR/AMD × 25 wk | No | 1/4 | |
| J | VCR/AMD/DOX/CTX × 15 mo | Yes | 0/4 | |
| L | VCR/AMD × 10 wk | No | 2/0 | |
| NWTS-4 | EE | VCR/AMD-std. × 25 wk | No | 8/9 |
| EE4A | VCR/AMD-PI × 18 wk | No | 7/6 | |
| K | VCR/AMD-std × 65 wk | No | 0/1 | |
| NWTS-5 | EE4A | VCR/AMD-PI × 18 wk | No | 8/19 |
FA, focal anaplasia; DA, diffuse anaplasia; VCR, vincristine; wk, weeks; mo, months; AMD, dactinomycin; std, standard dosing; PI, pulse intensive dosing; DOX, doxorubicin; CTX, cyclophosphamide; XRT, radiation therapy